Skip to content
Oxitriptan
Oxitriptan is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target proton-coupled amino acid transporter 2 and proton-coupled amino acid transporter 1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06A: Antidepressants
— N06AX: Other antidepressants in atc
— N06AX01: Oxitriptan
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Major depressive disorderD003865EFO_0003761F22—1—2—3
Obstructive sleep apneaD020181EFO_0003918G47.33———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Spinal cord injuriesD013119EFO_1001919—22——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ulcerative colitisD003093EFO_0000729K51—1———1
Crohn diseaseD003424EFO_0000384K50—1———1
FatigueD005221HP_0012378R53.83—1———1
AsthmaD001249EFO_0000270J45—1———1
ObesityD009765EFO_0001073E66.9—1———1
Fragile x syndromeD005600Q99.2—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SleepD012890GO_0030431————11
Gastrointestinal microbiomeD000069196————11
Type 2 diabetes mellitusD003924EFO_0001360E11————11
Type 1 diabetes mellitusD003922EFO_0001359E10————11
AffectD000339————11
Irritable bowel syndromeD043183EFO_0000555K58————11
Body compositionD001823————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameOXITRIPTAN
INNoxitriptan
Description
5-hydroxy-L-tryptophan is the L-enantiomer of 5-hydroxytryptophan. It has a role as a human metabolite, a plant metabolite and a mouse metabolite. It is a 5-hydroxytryptophan, a hydroxy-L-tryptophan and a non-proteinogenic L-alpha-amino acid. It is an enantiomer of a 5-hydroxy-D-tryptophan. It is a tautomer of a 5-hydroxy-L-tryptophan zwitterion.
Classification
Small molecule
Drug classantimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)O
Identifiers
PDB—
CAS-ID4350-09-8
RxCUI94
ChEMBL IDCHEMBL350221
ChEBI ID17780
PubChem CID439280
DrugBankDB02959
UNII IDC1LJO185Q9 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SLC36A2
SLC36A2
SLC36A1
SLC36A1
Organism
Homo sapiens
Gene name
SLC36A2
Gene synonyms
PAT2, TRAMD1
NCBI Gene ID
153201
Protein name
proton-coupled amino acid transporter 2
Protein synonyms
solute carrier family 36 (proton/amino acid symporter), member 2, Solute carrier family 36 member 2, Tramdorin-1, Transmembrane domain rich protein 1
Uniprot ID
Q7Z6B5
Mouse ortholog
Slc36a2 (246049)
proton-coupled amino acid transporter 2 (Q8JZP1)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 41 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
96 adverse events reported
View more details